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ABSTRACT
The Wilms’ tumour suppressor protein WT1 plays
a central role in the development of the kidney and
also other organs. WT1 can act as a transcription
factor with highly context-specific activator and
repressor functions. We previously identified Brain
Acid Soluble Protein 1 (BASP1) as a transcriptional
cosuppressor that can block the transcriptional
activation function of WT1. WT1 and BASP1 are
co-expressed during nephrogenesis and both pro-
teins ultimately become restricted to the podocyte
cells of the adult kidney. Here, we have analysed the
WT1/BASP1 complex in a podocyte precursor cell
line that can be induced to differentiate. Chromatin
immunoprecipitation revealed that WT1 and BASP1
occupy the promoters of the Bak, c-myc and podo-
calyxin genes in podocyte precursor cells. During
differentiation-dependent upregulation of podoca-
lyxin expression BASP1 occupancy of the podoca-
lyxin promoter is reduced compared to that of WT1.
In contrast, the repressive WT1/BASP1 occupancy
of the c-myc and Bak promoters is maintained and
these genes are downregulated during the differen-
tiation process. We provide evidence that the regu-
lation of BASP1 promoter occupancy involves the
sumoylation of BASP1. Our results reveal a dynamic
cooperation between WT1 and BASP1 in the regula-
tion of gene expression during differentiation.
INTRODUCTION
The Wilms’ tumour suppressor protein WT1 was identi-
ﬁed on the basis of its frequent mutation in Wilms’
tumours, a paediatric malignancy of the kidneys (1,2).
WT1 plays a central role in nephrogenesis and WT1 null
mice die in utero, displaying complete agenesis of the kid-
neys and also several other organs (3,4). WT1 is a nuclear
protein containing a zinc ﬁnger nucleic acid-binding
domain that is alternatively spliced, leading to insertion
of an additional three amino acids (KTS) between zinc
ﬁngers 3 and 4. This insertion produces a form of WT1
(+KTS) that has a high aﬃnity for RNA, while the –KTS
form binds DNA. These and other observations have
led to the proposal that the –KTS form of WT1 acts as
a transcriptional regulator, while the +KTS form plays
a role in RNA processing. Mice that express exclusively
either the +KTS or – KTS forms of WT1 show that WT1
–KTS plays a greater role in nephrogenesis and podocyte
diﬀerentiation (5).
The transcriptional regulatory properties of WT1 are
highly context-speciﬁc and can manifest as both transcrip-
tional activation and repression (6). Candidate target
genes of WT1 include signalling-related factors such as
amphiregulin (7,8), sprouty (9), platelet-derived growth
factor-A (PDGFA; 10,11), colony-stimulating factor-1
(CSF-1; 12) and Wnt 4 (13,14), regulators of cell
growth/survival such as Bcl2 (15), Bak (16,17), c-Myc
(18,19) and p21 (20) and also podocyte-speciﬁc proteins
such as nephrin (21,22) and podocalyxin (23,24). Studies
of these putative target genes in physiologically relevant
cells are few and thus we have very little understanding of
how WT1 regulates its target genes during development.
Several interaction partners have been described for
WT1 (6). It is likely that they provide speciﬁcity to WT1
function and determine whether WT1 acts as a transcrip-
tional activator or repressor. WT1 contains a suppression
domain at its N-terminus that inhibits the function of
the transcriptional activation domain (25). We previously
identiﬁed Brain Acid Soluble Protein 1 (BASP1) as a
WT1 transcriptional cosuppressor that mediates this
inhibition (26). Very little is known of BASP1 function
or structure, but it exists as multiple forms from 30 to
150kDa that are derived from post-translational modiﬁ-
cations and proteolytic processing (26,27). BASP1 is pres-
ent in the nephrogenic intermediates of the embryonic
kidney coincident with WT1 and, like WT1, BASP1
becomes restricted to the podocyte cells of the adult
kidney. In the present study we analyse WT1 and
BASP1 in a cell line model of podocyte diﬀerentiation.
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of the promoters of the endogenous podocalyxin, Bak and
c-myc genes. During podocyte diﬀerentiation BASP1 dis-
sociates from the podocalyxin promoter by a mechanism
involving BASP1 sumoylation and coincident with the
transcriptional upregulation of podocalyxin. Conversely,
WT1 and BASP1 remain bound to the Bak and c-myc
promoters, both of which show diﬀerentiation-dependent
repression.
MATERIALS AND METHODS
Celllines, immunofluorescence and transfection
MPC5, HEK 293 and K562 cells were cultured as
described previously (26,28,29). Transfection was per-
formed using Lipofectamine 2000 or calcium phosphate
as previously (25,30). Luciferase assays were performed
as described before (30). Immunoﬂuorescence was per-
formed as described previously (26). Antibodies against
WT1 were the C19 antibody (Santa Cruz), PML was
H238 (Santa Cruz), tubulin was DM1A (Sigma) and
synaptopodin was P19 (Santa Cruz). The aﬃnity-puriﬁed
rabbit anti-BASP1 antibodies have been described before
(26). Sheep anti-BASP1 antibodies were generated against
full-length BASP1 by Diagnostics Scotland and aﬃnity
puriﬁed.
Plasmids andproteins
pcDNA3 BASP1 has been described before (26). BASP1
K78R:K83R was generated using the Quickchange muta-
genesis kit (Stratagene). pRSET BASP1, producing
6-Histidine-tagged BASP1 was generated by cloning the
full-length human BASP1 cDNA into the plasmid pRSET
A (Invitrogen). Bacterial induction and lysate preparation
was performed as described (31) using bacteria trans-
formed with SUMO-3 sumoylation machinery (32) and
were a kind gift of James Witty and Andy Sharrocks.
The podocalyxin luciferase reporter was a kind gift
of Daniel Haber (23). Gel ﬁltration was performed
using a superose 6 column and Akta apparatus (GE
Healthcare). For the gel ﬁltration analysis MPC5 nuclear
extracts were prepared as described previously (25).
Nuclear extract measuring 0.25ml was applied to the
column at a ﬂow rate of 0.1ml/min and 250.5ml frac-
tions were collected. Proteins were precipitated as
described (26) and re-suspended in SDS–PAGE loading
dye. Subnuclear extracts were prepared as described
previously (33).
RNA and chromatinimmunoprecipitation (ChIP) analysis
Total RNA and cDNA were prepared using the Qiagen
Rneasy kit and Promega Access reverse transcriptase kit.
The primers for RT-PCR were; GAPDH, fwd TGA TGA
CAT CAA GAA GGT GGT GAA G, Rev TTC TTG
GAG GCC ATG TAG GCC AT; podocalyxin, fwd
GAA AGG AGC CCT CTG GAT GA, Rev GGG
CTC AGG CAC AAG TAG GT; WT1, fwd GAG
ACA YAC AGG TGT GAA ACC ATT, Rev GCC
ASS TGG AGT TTG GTC A; PDGFA, fwd GAC
GGT CAT TTA CGA GAT ACC TC, Rev CTA CGC
CTT CCT GTC TCC TC; CSF1, fwd ATG GAC ACC
TGA AGG TCC TG, Rev GTT AGC ATT GGG GGT
GTT GT; Bak, fwd CCA CAT CTG GAG CAG AGT C,
Rev CCT GCT GGT GGA GGT AAA AA; c-myc,
fwd GCG ACT CTG AAG AAG AG, Rev GTT GTG
CTG GTG AGT GGA GA. Annealing temperatures for
the PCR reactions were; WT1, 53
8C; GAPDH, 58
8C;
podocalyxin, 58
8C; PDGFA, 59
8C;CSF1, 58
8C; Bax,
58
8C; c-myc, 58
8C.
ChIP was performed using the ChIP kit (Upstate) as
before (34). Primers for Podocalyxin ChIP were; promo-
ter, fwd CCT CCC CAA ACG AAT AGG AT, Rev TCC
AAC AGC TGC TGA GAC AC, Internal region, fwd
CAT CCG TGT CTT CCC GTA GT, Rev TGG ATC
AAG TTG GCA GT; PDGFA, fwd TAA GGA TCT
GGA GGG TGC AG, Rev CCA AAA AGG GCA
TGA GAG TC; CSF, fwd GGT TCC ATG AGG GAC
TTG AA, Rev TGT GCA GCC TCC TCA AAG TA;
Bak, fwd GAG GGA GCT GCA GAG AGA AC, Rev
AAA CCT GGT GGG GAG TAA GG; c-myc, fwd TTC
TGA CTC GCT GTA GTA ATT CCA, Rev CCT GGC
TCG CAG ATT GTA AG. Annealing temperatures for
the PCR reactions were; podocalyxin, 58
8C; PDGFA,
59
8C;CSF1, 56.5
8C; Bax, 56.5
8C; c-myc, 59
8C.
RESULTS
WT1 and BASP1 expression in podocyteprecursor cells
The mouse cell line MPC5 was developed as a model of
podocyte diﬀerentiation and has previously been shown to
express podocyte-speciﬁc markers following induction of
diﬀerentiation (28,35). Figure 1A shows immunoﬂuores-
cence performed with anti-BASP1 and anti-WT1 antibod-
ies on the exponentially growing MPC5 cells. Both
WT1 and BASP1 are primarily nuclear and the merged
signal suggests that WT1 and BASP1 show partial
co-localization. As we have observed before with a range
of cell lines, the MPC5 cells contain several forms of
BASP1, which arise from proteolytic processing and
post-translational modiﬁcation, including myristoylation
(Figure 1B; lower panel input lane; 26). Our previous
work showed that diﬀerent cells lines express the various
forms of BASP1 in diﬀerent proportions. We demon-
strated previously by co-immunoprecipitation that the
40-kDa form of BASP1 (BASP140), but not the 30-kDa
form or the large forms (up to 150kDa), complexes with
WT1 in mouse M15 embryonic kidney cells (26). To deter-
mine the form of BASP1 that associates with WT1
in MPC5 cells we performed gel ﬁltration with whole
nuclear extracts and examined the fractions by immuno-
blotting with either anti-WT1 or anti-BASP1 antibodies
(Figure 1B). WT1 was present in high-molecular-weight
complexes of 700kDa. Signiﬁcantly, and consistent
with our previous data, BASP140 was present in the
same fractions as WT1 (26). The other forms of BASP1,
ranging from 30kDa to 150kDa, are present in lower
molecular weight complexes.
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We next transferred the MPC5 cells to 37
8C and removed
the g-interferon. This leads to downregulation of the tem-
perature-sensitive T-antigen, the cells cease to proliferate
and then undergo diﬀerentiation. Figure 2A shows a series
of panels of immunoﬂuorescence performed when the
MPC5 cells were switched to the non-permissive tempera-
ture and allowed to diﬀerentiate over 6 days. Analysis of
tubulin shows that between Days 3 and 4 the cells enlarge
and undergo a signiﬁcant restructuring within the cyto-
plasm. Detection of synaptopodin showed an elevation
in abundance after Day 3 and assembly into actin ﬁbres.
This is a hallmark of podocyte diﬀerentiation and is
consistent with previous studies with this cell line (28).
We also analysed BASP1 and WT1 by immunoﬂuores-
cence, neither of which showed any observable changes
during podocyte diﬀerentiation (data not shown).
RT-PCR was used to analyze the mRNA levels of WT1,
GAPDH (as a control) and a selection of previously pro-
posed WT1 target genes during the diﬀerentiation of
MPC5 cells (Figure 2B). WT1 mRNA levels showed a
small reduction when the cells were transferred to the
non-permissive temperature, but were maintained at simi-
lar levels during diﬀerentiation. The changes in expression
of the potential WT1 target genes could be grouped
into three categories. Firstly, CSF-1 and PDGFA both
showed increases in mRNA level from Day 3 onward of
the diﬀerentiation process. Secondly, Bak and c-myc both
showed diﬀerentiation-dependent decreases in mRNA.
Finally, podocalyxin mRNA revealed a sharp decrease
following induction of diﬀerentiation, but gradually
recovered over Days 2–5.
Promoter occupancy by WT1 and BASP1
We next determined if the distinct modes of change that we
observed in the regulation of the PDGFA and CSF1, Bak
and c-myc and podocalyxin genes could be explained by
changes in WT1/BASP1 occupancy of their promoter
regions. ChIP was performed with anti-WT1 and two dif-
ferent anti-BASP1 antibodies (raised in sheep, BASP1s and
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Figure 1. WT1 and BASP1 localization in MPC5 podocyte precursor
cells. (A) MPC5 cells were subject to immunoﬂuorescence with rabbit
anti-WT1 (red) and sheep anti-BASP1 (green) antibodies. A merge of
the two images is shown in the bottom right panel, along with enlarged
images of the two cells indicated. Cells were counterstained with
Hoechst. Below, control immunoﬂourescence with each of the sheep
and rabbit secondary antibodies is shown. (B) Gel ﬁltration was per-
formed with nuclear extracts prepared from MPC5 cells and the frac-
tions immunoblotted with either anti-WT1 (top) or rabbit anti-BASP1
antibodies (bottom). Calibration (in kilodalton) is above the autoradio-
graphs, fraction numbers are below and molecular weight markers
(in kilodalton) are at left. WT1, BASP140 and BASP152 are each indi-
cated by arrows. The WT1 complexes that co-fractionate with BASP1
are boxed. The dashed line indicates the alignment from two separate
gels that were immunoblotted together.
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Figure 2. Diﬀerentiation of MPC5 cells. (A) Mouse MPC5 cells were
diﬀerentiated for the times indicated at top. The cells were then ﬁxed
and subject to immunoﬂuorescence with either anti-tubulin or anti-
synaptopodin antibodies (both in green), counterstaining with
Hoechst. (B) MPC5 cells were diﬀerentiated for the number of days
indicated and total RNA prepared. Semi-quantitative RT-PCR was
performed to detect WT1, CSF1, PDGFA, Bak, c-myc, Podocalyxin
and GAPDH.
Nucleic Acids Research,2009, Vol. 37,No. 2 433rabbit, BASP1r) followed by ampliﬁcation of the regions
of the promoters that contain the proposed WT1-binding
sites (schematics for each promoter are shown in Figure 3).
First, we tested the PDGFA and CSF1 promoters, both of
which were upregulated during MPC5 cell diﬀerentiation
(Figure 3A). We could not detect binding of WT1 or
BASP1at either the PDGFA or CSF1 promoters, before
or after 5 days of diﬀerentiation. A control antibody (anti-
acetyl histone H3, aAcH3) did however precipitate the
CSF1 and PDGFA promoter regions.
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Figure 3. Promoter occupancy by WT1 and BASP1 in diﬀerentiating MPC5 cells. (A) ChIP was performed with undiﬀerentiated MPC5 cells (0) or
MPC5 cells that had diﬀerentiated for 5 days (5). The antibodies used in the ChIP were rabbit anti-GAL4 antibodies (aCtrl), anti-acetylated histone
H3 (aAcH3), rabbit anti-WT1 antibodies (aWT1), rabbit anti-BASP1 antibodies (aBASP1r) and sheep anti-BASP1 antibodies (aBASP1s). The
resultant samples were subject to ampliﬁcation by PCR using primers directed to the mouse PDGFA promoter (top) or CSF1 promoter (bottom). I is
1/50 of the input chromatin in each immunoprecipitation. A diagram of each promoter region is shown at right, with the positions of the WT1
DNA-binding sites and forward/reverse primer regions indicated. (B) ChIP was performed as in part A except that the Bak (top) and c-myc (bottom)
promoters were analysed. (C) As in (A) except that the analysis was performed with undiﬀerentiated MPC5 cells (0) and cells that had been allowed
to diﬀerentiate for 3 (3) and 5 (5) days. The bottom panel is ampliﬁcation of an internal region of the podocalyxin gene (Int.) from ChIP analysis of
undiﬀerentiated MPC5 cells.
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of which showed downregulation of the mRNA during
podocyte diﬀerentiation. ChIP revealed that both WT1
and BASP1 were present at the Bak and c-myc promoters
in undiﬀerentiated MPC5 cells (Figure 3B). After 5 days
of diﬀerentiation, WT1 and BASP1 remained bound to
the Bak and c-myc promoters. Thus, the ChIP data sug-
gest that the Bak and c-myc genes are bona ﬁde targets
of WT1/BASP1 in podocytes, but do not provide an
explanation for the downregulation of the activities of
these genes during the diﬀerentiation process.
Based on the expression proﬁle of podocalyxin during
MPC5 cell diﬀerentiation we performed ChIP analysis
at 0-, 3- and 5-day time points. In the undiﬀerentiated
podocyte cells, we detected both WT1 and BASP1at
the podocalyxin promoter (Figure 3C). At Day 3, WT1
and BASP1 were similarly engaged at the podocalyxin
promoter. However, we note that, compared to the
input chromatin, there was a signiﬁcant elevation in the
eﬃciency of ChIP, suggesting an increase in promoter
occupancy over the cell population. Thus, the reduction
in podocalyxin expression upon induction of diﬀerentia-
tion is concomitant with an increase in promoter occu-
pancy by WT1 and BASP1. At Day 5, we found that
the WT1 ChIP at the podocalyxin promoter remained
robust, but the BASP1 ChIP showed a signiﬁcant reduc-
tion (with both BASP1 antibodies) when compared with
WT1. Thus the subsequent recovery of podocalyxin
expression occurs when the BASP1 ChIP is reduced, but
WT1 remains at the promoter.
BASP140 ismodified during podocyte differentiation
We next sought to determine if the changes in WT1 and
BASP1 ChIP that we observed during the course of MPC5
cell diﬀerentiation were due to changes in WT1 and/or
BASP1 abundance. We ﬁrst immunoblotted extracts
from a diﬀerentiation time course with anti-WT1 antibo-
dies (Figure 4A, top panel). The level of WT1 increased
over the ﬁrst 3 days of podocyte diﬀerentiation and then
gradually returned to the same level as that observed prior
to diﬀerentiation. We note that our RT-PCR analysis
revealed a decrease in WT1 mRNA (Figure 2B) suggesting
that the WT1 protein is stabilized upon MPC5 cell diﬀer-
entiation. Indeed, recent studies have shown that WT1 is
subject to regulated degradation by the proteasome (36).
Analysis of the same diﬀerentiation time-course samples
with anti-BASP1 antibodies revealed a signiﬁcant change
in the BASP1 proﬁle (Figure 4A, lower panel shown as
short and long exposures). Speciﬁcally, over Days 3–6,
BASP140 showed a dramatic reduction and there is a con-
comitant appearance of BASP1 immunoreactive bands
around the 60-kDa region. Such a size diﬀerence is con-
sistent with the potential sumoylation of BASP140. BASP1
contains two highly conserved consensus SUMO-
modiﬁcation sites (K78 and K83; Figure 4B). We gener-
ated a double substitution mutant in which these
two lysine residues were substituted with arginine
(K78R:K83R). Wild-type HA-tagged BASP1 or the
BASP1 K78R:K83R derivative were transfected into 293
cells along with either his-tagged SUMO-1 or his-tagged
SUMO-3. Lysates were prepared under denaturing condi-
tions and the his-tagged SUMO puriﬁed by nickel chelate
aﬃnity chromatography. The puriﬁed products were
resolved by SDS–PAGE and immunoblotted with anti-
HA antibodies (Figure 4B). The results show that wild-
type BASP1, but not the BASP1 K78R:K83R derivative
attaches speciﬁcally to SUMO-3, forming a product of
60kDa. To conﬁrm the direct sumoylation of BASP1,
we used a bacterial system that expresses the components
required to attach SUMO-3. Control bacteria, or bacteria
that express SUMO-3, were transformed with a plasmid
driving expression of his-tagged BASP1 or, as a control,
GST. Three hours after induction, whole-cell lysates were
prepared, resolved by electrophoresis and immunoblotted
with anti-BASP1 antibodies (Figure 4C). In the presence
of SUMO-3, slower migrating forms of BASP1 were
observed that are consistent with the single and multiple
attachment of SUMO-3 to BASP1. Indeed, SUMO-3 itself
contains a consensus sumoylation motif and hence
attaches to its substrates as chains of variable length (37).
BASP1sumoylation canaffect its subnuclear localization
Sumoylation can elicit direct eﬀects on transcriptional
regulation (37,38). We therefore tested whether BASP1
(K78R:K83R) exhibited diﬀerent transcription properties
when compared with wild-type BASP1. K562 cells, which
have low endogenous BASP1 but contain WT1 (26), were
transfected with a luciferase reporter containing the intact
podocalyxin promoter or a derivative that lacks the WT1
response element (WRE; 23). The wild-type podocalyxin
promoter shows a higher activity than the WRE deriva-
tive, consistent with activation of the podocalyxin promo-
ter by WT1 (Figure 5A). As we observed in our previous
analyses of the amphiregulin promoter in K562 cells (26),
ectopic expression of BASP1 suppresses WT1-mediated
transcriptional activation of the podocalyxin promoter.
The mutant BASP1 derivative (K78R:K83R) also
represses the activity of podocalyxin promoter in a
manner dependent upon the WT1 DNA-binding sites.
Similar eﬀects were observed when we tested a Bak pro-
moter reporter construct and also an amphiregulin
promoter reporter construct (data not shown).
BASP1 can repress transcription independently of WT1
when linked directly to GAL4 (26). We therefore tested
BASP1 K78R:K83R in this context with the ‘high basal’
thymidine kinase reporter (Figure 5B; 25) or a minimal
core promoter driven to high levels of expression by
LexA-VP16 (Figure 5C; 39), in both cases linked to
ﬁve GAL4 DNA-binding sites. A GAL4-fusion protein
containing the transcriptional repression domain of even
skipped (GAL4-EVE) was used as a positive control (40).
The results show that, at both promoters, GAL4-BASP1
(K78R:K83R) exhibits a diminished ability to repress
transcription when compared to a GAL4-fusion con-
taining wild-type BASP1. Taken together, the data of
Figures 5A–C suggest that sumoylation of BASP1 is not
required for its ability to block the transcriptional activa-
tion domain of WT1 per se, but can potentially aﬀect its
intrinsic transcriptional repression activity.
Nucleic Acids Research,2009, Vol. 37,No. 2 435Sumoylation of transcription factors can also result in
their re-localization within a cell (e.g. to the PML bodies;
37,38). Interestingly, in our immunoﬂuorescence studies
BASP1 showed a distinct speckled pattern within the
nucleus (Figure 1A), which we also observed with a dif-
ferent anti-BASP1 antibody (Figure 6A). Co-immuno-
ﬂuorescence with anti-BASP1 and anti-PML antibodies
followed by examination using a DeltaVision microscope
revealed that BASP1 is indeed present within PML bodies
in MPC5 cells (Figure 6B).
To determine the potential eﬀects of BASP1 sumoyla-
tion on its subnuclear distribution we transfected wild-
type BASP1 or the BASP1 K78R:K83R mutant derivative
into K562 cells (Figure 6C, left panel), prepared subnuc-
lear fractions and analysed them by western blotting
with anti-BASP1 antibodies (Figure 6C, right panel).
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Figure 4. BASP1 undergoes modiﬁcation during podocyte diﬀerentiation. (A) MPC5 cells were diﬀerentiated for the number of days indicated,
whole-cell lysates were then prepared and immunoblotted with anti-WT1 (top), anti-BASP1 (middle) or anti-tubulin (bottom) antibodies. A short and
long exposure of the anti-BASP1 blot are shown. Molecular weight markers (in kilodalton) are shown at left. WT1, tubulin, BASP140 and the 60-
kDa forms of BASP1 are indicated. (B) A schematic of BASP1 indicating the myristoylation motif (m), nuclear localization sequence (NLS),
potential phosphorylation sites (P) and conserved potential sumo-modiﬁcation sites (S). The boxed regions are PEST sequences. Below, plasmids
driving expression of wild-type HA-tagged BASP1 or BASP1 K78R:K83R were transfected into 293 cells alone, or with a plasmid driving expression
of either his-tagged SUMO-1 or SUMO-3. Forty-eight hours later, extracts were prepared under denaturing conditions and the his-tagged derivatives
puriﬁed and immunoblotted with anti-HA antibodies. Molecular weight markers (in kilodalton) are shown at left. The autoradiograph below
shows an immunoblot with anti-BASP1 antibodies of whole-cell lysates before nickel chelate aﬃnity puriﬁcation. (C) GST or his-tagged BASP1
were expressed in Escherichia coli that either harbour or lack the apparatus to attach sumo-3. Bacterial lysates were resolved by electrophoresis and
immunoblotted with anti-BASP1 antibodies. Molecular weight markers are shown at left. BASP152 and sumo-dependent modiﬁed forms of BASP1
are indicated by arrows.
436 Nucleic Acids Research, 2009, Vol. 37, No. 2The 60-kDa form of BASP1 in the nuclear matrix
showed a substantial reduction in cells transfected with
the mutant BASP1 K78R:K83R when compared to
wild-type BASP1. Signiﬁcantly, concomitant with the
ablation of this nuclear matrix-speciﬁc form of BASP1
caused by the K78R:K83R mutation, there was a signiﬁ-
cant increase in BASP140. Taken together with the data of
Figure 4, these results suggest that the 60-kDa form of
BASP1 arises from sumoylation of BASP140 which then
accumulates in the nuclear matrix. We therefore prepared
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Figure 5. BASP1 exhibits sumo-dependent and sumo-independent functions as a WT1 transcriptional cosuppressor. (A) K562 cells were transfected
with 0.5mg of podocalyxin promoter-luciferase (LUC) reporter with or without (WRE) the WT1-binding sites. Where indicated pcDNA3-
HA-BASP1 or pcDNA3-HA-BASP1 K78R:K83R (0.1mg and 0.5mg) was also transfected. Forty-eight hours later, cells were harvested and luciferase
activity was measured and is presented is presented relative to the luciferase activity of the wild-type podocalyxin reporter in the absence of BASP1.
Bars are the mean of three independent experiments with standard deviation. Asterisks denote t-test signiﬁcance better than 95%. At right an
immunoblot of whole-cell lysates with anti-BASP1 antibodies is shown, (B) Human embryonic kidney 293 cells were transfected with the G5TKCAT
reporter and either pcDNA3 or pcDNA3- GAL4 (residues 1–94), GAL4-EVE, GAL4-BASP1 or GAL4-BASP1 K78R:K83R. Forty-eight hours
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the mean of three independent experiments with standard deviation. (C) As in (B) except that the Lex/Gal luciferase reporter was used and a plasmid
driving expression of LexA-VP16 was included.
Nucleic Acids Research,2009, Vol. 37,No. 2 437subnuclear fractions from undiﬀerentiated MPC5 cells
and also cells that had been allowed to diﬀerentiate for
5 days. BASP140 was present in the chromatin fraction of
the undiﬀerentiated MPC5 cells (Figure 6D). As expected
from the data of Figure 4A, at Day 5 of diﬀerentiation,
BASP140 is no longer present in any of the fractions.
However, a 60-kDa form of BASP1 was observed in
the matrix fraction of the diﬀerentiated cells. These results
are consistent with the sumoylation and nuclear redistri-
bution of BASP140 during podocyte diﬀerentiation.
DISCUSSION
Here we have analysed WT1 and BASP1 in a cell line
model of podocyte diﬀerentiation, a process known to
be dependent on WT1 function as a transcription factor.
WT1 and BASP1 both localize at the Bak, c-myc and
podocalyxin gene promoters, providing the ﬁrst demon-
stration that BASP1 can localize to gene promoters that
are regulated by WT1. We were unable to detect either
WT1 or BASP1at the CSF-1 or PDGFA promoters.
It is possible that PDGFA and CSF-1 are not regulated
by WT1 in the MPC5 cell line, but we cannot rule out
restricted epitope accessibility of WT1 and BASP1at
these speciﬁc promoters.
We found that BASP1 can be sumoylated and presented
evidence that this is a dynamic process during podocyte
diﬀerentiation. Sumoylation of BASP140 can result in its
redistribution within the nucleus from the chromatin to
the nuclear matrix. We also found that, while sumoylation
of BASP1 was not required for its function as a WT1
transcriptional cosuppressor per se, a GAL4-BASP1 deri-
vative that was unable to undergo sumo-modiﬁcation was
less eﬀective as a transcriptional repressor. Thus, the
major eﬀect of sumoylation of BASP1 is its redistribution
within the nucleus. In addition, although not necessary,
sumoylation of BASP1 can potentially augment its WT1
transcriptional cosuppressor function.
The changes in BASP1 occupancy at the podocalyxin
promoter during diﬀerentiation that we observed are
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438 Nucleic Acids Research, 2009, Vol. 37, No. 2consistent with the subnuclear re-localization of BASP1 in
a sumo-dependent manner. Moreover, there is a direct
correlation between the presence of BASP140 in the chro-
matin, occupancy by BASP1 of the WT1-bound podoca-
lyxin promoter and changes in podocalyxin mRNA that
occur between Days 3 and 5 of podocyte diﬀerentiation.
Our results therefore provide a mechanism by which
WT1-mediated transcriptional activation of the podoca-
lyxin gene is modulated by BASP1 during podocyte diﬀer-
entiation (Figure 7, left panel). It will be interesting
to determine if the co-activator CBP is recruited to the
podocalyxin promoter by WT1, and if this event is regu-
lated by the WT1-BASP1 interaction (41).
Unlike the podocalyxin gene, the Bak and c-myc genes
were downregulated during podocyte diﬀerentiation.
ChIP analysis revealed that WT1 and BASP1 both
remained bound to the Bak and c-myc promoters during
the diﬀerentiation process (Figure 7, right panel). The
maintenance of BASP1at the Bak and c-myc promoters
is consistent with their transcriptional suppression during
MPC5 cell diﬀerentiation. Although the subnuclear
fractionation of the MPC5 cells revealed the depletion
of BASP140 from the chromatin and accumulation in the
matrix (Figure 6D), the retained ChIP of BASP1at the
Bak and c-myc promoters suggests either that some
BASP1 remains within the chromatin, but is below
the level of detection in this assay. Whether or not the
retained BASP1 is sumoylated remains to be determined,
but could potentially contribute to the downregulation of
the Bak and c-myc genes during diﬀerentiation.
Taken together, our data suggest that WT1/BASP1
cooperation in transcriptional regulation is complex.
Although the diﬀerentiation state-dependent presence of
BASP1at the podocalyxin and Bak/c-myc promoters is
consistent with their upregulation and downregulation
respectively, it is not clear why BASP1 should selectively
dissociate from speciﬁc gene promoters. It is very likely
that other factors are involved in the WT1-BASP1
dynamic. Indeed, our gel ﬁltration data (Figure 1A) sug-
gests that the WT1 and BASP1 are contained in complexes
of at least 700kDa.
The MPC5 cells used in this study provide a model for
the diﬀerentiation of podocytes both morphologically and
in their gene expression proﬁle (28). However, we found
that at the permissive temperature, when the MPC5 cells
are immortalized by expression of T-antigen, the level
of podocalyxin expression was elevated and only reduced
once the T-antigen was inactivated. This coincides with a
sharp increase in WT1 protein. However, other factors
could contribute to the elevated level of podocalyxin
mRNA in the immortalized MPC5 cells. For example,
previous studies have shown that p53 transcriptionally
represses the podocalyxin promoter (24). Moreover, the
cell-type speciﬁc expression of podocalyxin is dependent
upon correct methylation of its promoter (42). Both of
these processes are sensitive to T-antigen, suggesting that
the ground state of podocalyxin expression in MPC5 cells
might only be achieved when T-antigen is inactivated.
Previous studies have shown that WT1 can also be
sumoylated and that this speciﬁcally involves SUMO-1
(43). Our ﬁnding that BASP1 is modiﬁed by SUMO-3,
but not by SUMO-1, provides potential for diﬀerential
regulation of WT1 and BASP1 by sumoylation. Future
studies will focus on how regulatory modiﬁcations of
WT1 and BASP1 can modulate their cooperation in the
control of transcriptional regulation in development and
tumourigenesis.
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